RT Journal Article
T1 Oral anticoagulation in octogenarians with atrial fibrillation.
A1 Hugo, González Saldivar
A1 Figueiras-Graillet, Lourdes M
A1 Anguita, Manuel
A1 Marín, Francisco
A1 Bertomeu, Vicente
A1 Roldán, Inmaculada
A1 Ruiz, Martín
A1 Muñiz, Javier
A1 Martínez-Sellés, Manuel
A1 FANTASIIA registry investigators (see Appendix), 
K1 Age
K1 Atrial fibrillation
K1 Octogenarians
K1 Time in therapeutic range
K1 Vitamin K antagonists
AB Vitamin K antagonists (VKAs) are still largely employed, even in nonvalvular atrial fibrillation (AF). Our aim was to study the clinical profile of octogenarians treated with oral anticoagulation and to study the effect of age on the quality of VKAs anticoagulation. Data are from a prospective national registry in an adult Spanish population of nonvalvular AF. We included 1637 patients who had been receiving VKAs for at least 6months before enrolment. Mean age was 73.8±9.4years. Patients aged >80years (N=429) had a high risk profile with higher risk of stroke and bleeding than younger patients; CHA2DS2-VASc (Cardiac failure, Hypertension, Age>74, Diabetes, Stroke, Vascular disease, Age 65-74years, and Sex category) 4.5±1.3 vs. 3.5±1.6, p80years (N=429) had a high risk profile with higher risk of stroke and bleeding than younger patients; CHA2DS2-VASc (Cardiac failure, Hypertension, Age>74, Diabetes, Stroke, Vascular disease, Age 65-74years, and Sex category) 4.5±1.3 vs. 3.5±1.6, p74, Diabetes, Stroke, Vascular disease, Age 65-74years, and Sex category) 4.5±1.3 vs. 3.5±1.6, p64years), Drugs/alcohol concomitantly) 2.4±0.9 vs. 1.9±1.1, p In this large registry octogenarians with nonvalvular AF had high risk of stroke and bleeding and frequent renal disease. VKAs anticoagulation quality was similar in octogenarians and in younger patients.
YR 2016
FD 2016-08-04
LK http://hdl.handle.net/10668/10362
UL http://hdl.handle.net/10668/10362
LA en
DS RISalud
RD Apr 8, 2025